Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥3,170 JPY
Change Today -55.00 / -1.71%
Volume 130.4K
4585 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

umn pharma inc (4585) Snapshot

Open
¥3,210
Previous Close
¥3,225
Day High
¥3,280
Day Low
¥3,125
52 Week High
08/27/14 - ¥3,960
52 Week Low
05/26/14 - ¥2,503
Market Cap
30.3B
Average Volume 10 Days
92.1K
EPS TTM
¥-452.34
Shares Outstanding
9.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UMN PHARMA INC (4585)

Related News

No related news articles were found.

umn pharma inc (4585) Related Businessweek News

No Related Businessweek News Found

umn pharma inc (4585) Details

UMN Pharma Inc. develops and manufactures biopharmaceuticals in Japan and internationally. Its products include UMN-0502, a seasonal influenza vaccine; UMN-0501 and UMN-0901, which are pandemic influenza vaccines; UMN-2003, a norovirus/rotavirus vaccine; and UMN-2002, a norovirus vaccine. The company was founded in 2004 and is headquartered in Yokohama, Japan.

96 Employees
Last Reported Date: 03/30/15
Founded in 2004

umn pharma inc (4585) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

umn pharma inc (4585) Key Developments

UMN Pharma Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year Ending December 31, 2015

UMN Pharma Inc. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced net sales of JPY 42 million against JPY 70 million a year ago. Operating loss was JPY 485 million against JPY 1,111 million a year ago. Ordinary loss was JPY 461 million against JPY 1,195 million a year ago. Net loss was JPY 457 million or JPY 47.86 per basic share against JPY 904 million or JPY 107.14 per basic share a year ago. Net cash outflow from operating activities was JPY 848,714,000 against net cash flow from operating activities of JPY 2,073,493,000 a year ago. Purchase of property, plant and equipment was JPY 1,400,000 compared to JPY 310,000 for the same period a year ago. Purchases of intangible fixed assets were JPY 216,000. Loss before income taxes and minority interests was JPY 461,436,000 against JPY 948,209,000 a year ago. The company provided earnings guidance for the full year ending December 31, 2015. For the full year ending December 31, 2015, the company expects to report net sales of JPY 5,224 million, operating loss of JPY 878 million, ordinary loss of JPY 1,025 million and net loss of JPY 1,033 million or JPY 108.14 per share.

UMN Pharma Inc. to Report Q1, 2015 Results on Apr 30, 2015

UMN Pharma Inc. announced that they will report Q1, 2015 results on Apr 30, 2015

UMN Pharma Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year Ending December 31, 2015

UMN Pharma Inc. announced consolidated and non-consolidated earnings results for the year ended December 31, 2014. For the full year, on consolidated basis, the company announced net sales of JPY 1,108.522 million against JPY 93.379 million a year ago. Operating loss was JPY 3,942.694 million against JPY 4,421.977 million a year ago. Loss before income taxes and minority interests was JPY 4,002.394 million against JPY 4,140.486 million a year ago. Net loss was JPY 3,961.233 million or JPY 452.34 per basic share against JPY 3,717.117 million or JPY 491.59 per basic share a year ago. Net cash provided by operating activities was JPY 314.665 million against net cash used in operating activities of JPY 3,578.459 million a year ago. Purchase of tangible fixed assets was JPY 5.004 million compared to JPY 3,894.139 million for the same period a year ago. Purchases of intangible fixed assets was JPY 3.306 million compared to JPY 425.671 million for the same period a year ago. For the full year, on non-consolidated basis, the company announced net sales of JPY 1,108 million against JPY 92 million a year ago. Operating loss was JPY 2,861 million against JPY 3,301 million a year ago. Net loss was JPY 2,822 million or JPY 322.29 per basic share against JPY 3,207 million or JPY 424.14 per basic share a year ago. The company provided earnings guidance for the full year ending December 31, 2015. For the full year ending December 31, 2015, the company expects to report net sales of JPY 5,224 million, operating loss of JPY 878 million, ordinary loss of JPY 1,025 million and net loss of JPY 1,033 million or JPY 108.14 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4585:JP ¥3,170.00 JPY -55.00

4585 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4585.
View Industry Companies
 

Industry Analysis

4585

Industry Average

Valuation 4585 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.2x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UMN PHARMA INC, please visit www.umnpharma.com/en. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.